SCHEMBL13620068

SCHEMBL13620068

CCNC(=O)C1(C(=O)N(C)c2ccc(F)cc2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR2 P50052 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
FOLH1 Q04609 1/20 0.36
ALDH1A1 P00352 2/20 0.36
OPRM1 P35372 2/20 0.35
OPRL1 P41146 1/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
FAAH O00519 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
ALOX12 P18054 1/20 0.34
MAPK1 P28482 1/20 0.34
MTOR P42345 1/20 0.34
RAB9A P51151 1/20 0.34
DRD2 P14416 1/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RIPK1 Q13546 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14045178 0.86 OPRM1 (0.46) ALDH1A1OPRM1OPRL1TSHRRAB9A
SCHEMBL14873216 0.84 AGTR2 (0.36) AGTR2FOLH1ALDH1A1RAB9ADRD2
SCHEMBL14817541 0.81 CYP3A4 (0.35) AGTR2ALDH1A1HPGDCYP3A4DRD2
SCHEMBL13927587 0.81 KMT2A (0.40) AGTR2FOLH1ALDH1A1HPGDTSHR
SCHEMBL307214 0.79 AGTR2 (0.43) AGTR2FOLH1ALDH1A1POLQ
SCHEMBL10172489 0.78 DDB1 (0.40) AGTR2ALDH1A1OPRM1OPRL1TSHR
SCHEMBL18542859 0.78 NOTUM (0.37) AGTR2FOLH1ALDH1A1OPRM1TSHR
SCHEMBL22265647 0.78 GAA (0.39) AGTR2ALDH1A1POLQ
SCHEMBL18256941 0.78 AGTR2 (0.38) AGTR2ALDH1A1DRD2POLQ
SCHEMBL22766292 0.77 ALDH1A1 (0.41) ALDH1A1TSHRCYP3A4HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors Mirati Therapeutics, Inc. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MAP3K19, MAP3K9, MAP4K2 AGTR2 1970/4885HRH3 2718/4885FOLH1 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.